Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment
March 4, 2016Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2
Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …
Almost half of US physicians will prescribe more biosimilars, according to survey
March 4, 2016Medical Communications Obama, US, biosimilar, patent, prescribing
New data published by InCrowd has suggested that US physicians are very amenable to the prescription of biosimilars, with some …
Baxalta seeks European marketing rights for haemophilia drug
March 3, 2016Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta
Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …
UCB targets regulatory filing for its osteoporosis drug in 2016
March 3, 2016Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis
Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …
Merck announces drug discovery collaboration with European Molecular Biology Laboratory
March 3, 2016Research and Development Cancer, Merck, biomarkers
Merck has announced that it has entered into a research collaboration with the European Molecular Biology Laboratory (EMBL), that will …
Amgen sues Novartis over Enbrel biosimilar
March 3, 2016Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars
Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …
Valeant company group chairman and executive vice president resigns
March 3, 2016Medical Communications, Sales and Marketing Valeant, appointed, resignation
In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …
CHMP recommends Sanofi’s two-dose schedule HPV vaccine
March 3, 2016Research and Development HPV vaccine, MSD, Sanofi Pasteur
Sanofi Pasteur’s and MSD’s vaccine against human papillomavirus (HPV), Gardasil 9, has received a positive opinion from the European Medicine …
Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment
March 2, 2016Sales and Marketing Novo Nordisk, Xultophy, diabetes
Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
Bill Griffiths joins NDA group as general manager UK
March 2, 2016Medical Communications NDA Group
Industry veteran Bill Griffiths has joined NDA Group to head up the company’s UK consulting team and NDA’s advisory board. …
FDA approves Gilead’s Odefsey for treatment of HIV-1 infection
March 2, 2016Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …
Janssen slams NICE decision on Imbruvica
March 2, 2016Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica
Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
Top 10 medicines issued in England by prescription cost in 2014-15
March 2, 2016Research and Development, Sales and Marketing Cost, Humira, NHS, prescription
AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …
Clinton steps up attacks on Valeant in latest campaign advert
March 2, 2016Research and Development, Sales and Marketing Hilary Clinton, Valeant
This is not the first time the pharma industry has drawn the ire of the US presidential hopefuls, but Hilary …
LEO Pharma UK/Ireland appoints new dermatology director
March 2, 2016Medical Communications, Sales and Marketing
LEO Pharma has appointed Michael Hinchy as dermatology director with responsibility for its UK/Ireland affiliate. Michael brings over 16 years …
Chi-Med starts Phase II trial for thyroid cancer drug
March 2, 2016Research and Development Chi-Med
Hutchison China MediTech (Chi-Med) says its unit Hutchison MediPharma (HMP) has initiated mid-stage trials for sulfatinib to treat differentiated thyroid …
Ferring names Aaron Graff CEO of US holding company
March 2, 2016Medical Communications
Swiss fertility treatment company Ferring Pharmaceuticals on Tuesday named Aaron Graff the chief executive of its US unit, Ferring Holding. …
Merck begins late-stage trials of Humira biosimilar
March 2, 2016Research and Development, Sales and Marketing AbbVie, Humira, Merck, biosimilars
Merck has announced the beginning of a global phase III study of its Humira (adalimumb) biosimilar, MSB11022, in chronic plaque …
Wave expands team with new appointments
March 1, 2016Medical Communications
Medical education specialist, Wave, has made five new appointments, which the company says reflects the growth in its business over …
Exelixis signs $200 million licensing deal for cancer drug
March 1, 2016Research and Development, Sales and Marketing Cancer, Cometriq, Exelixis, ipsen
Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
